When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?

abobotulinumtoxinA maximal effect non‐linear random coefficient repeat injection upper limb spastic paresis

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2021
Historique:
received: 18 02 2020
revised: 05 08 2020
accepted: 28 08 2020
entrez: 5 2 2021
pubmed: 6 2 2021
medline: 6 2 2021
Statut: epublish

Résumé

Repeated injection cycles with abobotulinumtoxinA, a botulinum toxin type A, are recommended in current clinical guidelines as a treatment option for adults with upper limb spastic paresis. However, the magnitude of the maximal therapeutic effect of repeated abobotulinumtoxinA treatment across different efficacy parameters and the number of injection cycles required to reach maximal effect remain to be elucidated. Here, we present a

Identifiants

pubmed: 33543139
doi: 10.1093/braincomms/fcaa201
pii: fcaa201
pmc: PMC7850141
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcaa201

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Curr Opin Neurol. 2001 Dec;14(6):771-6
pubmed: 11723387
Clin Rehabil. 2020 Jun;34(6):803-811
pubmed: 32336148
Neurology. 2016 May 10;86(19):1818-26
pubmed: 27164716
Lancet Neurol. 2015 Oct;14(10):992-1001
pubmed: 26318836
Am J Phys Med Rehabil. 2015 Mar;94(3):229-38
pubmed: 25299523
J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1547-51
pubmed: 15489384
Muscle Nerve. 2018 Feb;57(2):245-254
pubmed: 28590525
Int J Clin Pract. 2008 Aug;62(8):1147-58
pubmed: 18564199
Pharm Stat. 2018 Sep;17(5):515-526
pubmed: 29781237
Neurology. 2004 Nov 23;63(10):1971-3
pubmed: 15557529
Eur J Phys Rehabil Med. 2010 Sep;46(3):411-21
pubmed: 20927007
Int J Neurosci. 2018 Nov;128(11):1030-1039
pubmed: 29619890
Arch Phys Med Rehabil. 2002 Oct;83(10):1349-54
pubmed: 12370866

Auteurs

Jean-Michel Gracies (JM)

UR 7377 BIOTN, Université Paris-Est Créteil, Service de Rééducation Neurolocomotrice, Hôpitaux Universitaires Henri Mondor, Créteil, France.

Robert Jech (R)

Department of Neurology and Center of Clinical Neuroscience, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Peter Valkovic (P)

2nd Department of Neurology, Comenius University Faculty of Medicine and University Hospital Bratislava, Bratislava, Slovak Republic.

Philippe Marque (P)

Service de médecine physique et réadaptation, Hôpital Rangueil, Toulouse, France.

Michele Vecchio (M)

Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Physical Medicine and Rehabilitation Unit, A.O.U. Policlinico Vittorio Emanuele, Catania, Italy.

Zoltan Denes (Z)

Brain Injury Rehabilitation Unit, National Institute for Medical Rehabilitation, Budapest, Hungary.

Claire Vilain (C)

Ipsen Pharma, Les Ulis, France.

Bruno Delafont (B)

Delafont Statistics, Alençon, France.

Philippe Picaut (P)

Ipsen Pharma, Les Ulis, France.

Classifications MeSH